Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 58
- Registration Number
- NCT00005601
- Locations
- 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
🇺🇸CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 48
- Registration Number
- NCT00026403
- Locations
- 🇺🇸
Altru Cancer Center, Grand Forks, North Dakota, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-18
- Target Recruit Count
- 5
- Registration Number
- NCT00021112
- Locations
- 🇳🇱
Academisch Ziekenhuis Utrecht, Utrecht, Netherlands
🇧🇪Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇳🇱University Hospital - Rotterdam Dijkzigt, Rotterdam, Netherlands
Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 51
- Registration Number
- NCT00030576
- Locations
- 🇨🇦
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Queen's University, Kingston, Ontario, Canada
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 29
- Registration Number
- NCT00003377
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00040872
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer
- Conditions
- Locations
- 🇫🇷
CHR de Grenoble - La Tronche, Grenoble, France
🇫🇷C.H. Senlis, Senlis, France
🇫🇷Centre Hospitalier Regional Metz Thionville, Thionville, France
Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00019864
- Locations
- 🇺🇸
Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00049348
- Locations
- 🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Hematology and Oncology Associates, Chicago, Illinois, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00021320
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.